Tags

Type your tag names separated by a space and hit enter

The clinical management of hyperphosphatemia.
J Nephrol 2005 May-Jun; 18(3):221-8JN

Abstract

As renal function declines in patients with end-stage renal disease (ESRD), excess dietary phosphorus accumulates in the bloodstream. Routine dialysis removes up to 70% of absorbed phosphorus; therefore, hyperphosphatemia is found in the majority of patients with ESRD. The consequences of this imbalance include secondary hyperparathyroidism and osteodystrophy. Recent studies have also documented that hyperphosphatemia can lead to soft-tissue and vascular calcification; the latter is strongly associated with cardiovascular disease and, thus, increased mortality and morbidity. The reduction of phosphorus levels is, therefore, an important therapeutic target in this patient group. Management of hyperphosphatemia using conventional phosphate binders is not always successful. However, emerging therapies aim to reduce the incidence of hyperparathyroidism, bone disease, and calcification in this patient population. In this article, the consequences of hyperphosphatemia are reviewed, and recent developments in the treatment of the condition are discussed.

Authors+Show Affiliations

Klinikum der Universitat Heidelberg, Heidelberg, Germany. E.Ritz@t-online.de

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16013007

Citation

Ritz, Eberhard. "The Clinical Management of Hyperphosphatemia." Journal of Nephrology, vol. 18, no. 3, 2005, pp. 221-8.
Ritz E. The clinical management of hyperphosphatemia. J Nephrol. 2005;18(3):221-8.
Ritz, E. (2005). The clinical management of hyperphosphatemia. Journal of Nephrology, 18(3), pp. 221-8.
Ritz E. The Clinical Management of Hyperphosphatemia. J Nephrol. 2005;18(3):221-8. PubMed PMID: 16013007.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The clinical management of hyperphosphatemia. A1 - Ritz,Eberhard, PY - 2005/7/14/pubmed PY - 2005/10/26/medline PY - 2005/7/14/entrez SP - 221 EP - 8 JF - Journal of nephrology JO - J. Nephrol. VL - 18 IS - 3 N2 - As renal function declines in patients with end-stage renal disease (ESRD), excess dietary phosphorus accumulates in the bloodstream. Routine dialysis removes up to 70% of absorbed phosphorus; therefore, hyperphosphatemia is found in the majority of patients with ESRD. The consequences of this imbalance include secondary hyperparathyroidism and osteodystrophy. Recent studies have also documented that hyperphosphatemia can lead to soft-tissue and vascular calcification; the latter is strongly associated with cardiovascular disease and, thus, increased mortality and morbidity. The reduction of phosphorus levels is, therefore, an important therapeutic target in this patient group. Management of hyperphosphatemia using conventional phosphate binders is not always successful. However, emerging therapies aim to reduce the incidence of hyperparathyroidism, bone disease, and calcification in this patient population. In this article, the consequences of hyperphosphatemia are reviewed, and recent developments in the treatment of the condition are discussed. SN - 1121-8428 UR - https://www.unboundmedicine.com/medline/citation/16013007/full_citation L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=16013007.ui DB - PRIME DP - Unbound Medicine ER -